Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial

German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis. Their drug, Cyltezo, a biosimilar to AbbVie's ... Read More